Nvidia-backed AI drugmaker Iambic Therapeutics files for U.S. IPO
Iambic Therapeutics, an artificial intelligence-driven drug discovery company backed by Nvidia (NVDA), has filed to go public in the United States. The San Diego-based biotech firm plans to list on Nasdaq under the ticker symbol IAM following its initial public offering filing. The IPO is expected to provide Iambic with capital for further development of AI-powered drug discovery platforms and expansion into new therapeutic areas. Nvidia's involvement highlights growing interest in leveraging artificial intelligence within pharmaceutical research, a sector increasingly adopting advanced computational tools to accelerate innovation and reduce costs. This move reflects broader trends as biotech firms seek public market funding amid rising demand for data-driven healthcare solutions.
Tickers: $NVDA
Topics: AI Drug Discovery Biotechnology Initial Public Offering (IPO)